Cancer theory faces doubts

OSI Pharmaceuticals, based in Melville, New York, is already pursuing EMT inhibitors as possible cancer treatments, as are several academic labs. "EMT is really becoming a popular subject," says Shoukat Dedhar, a cancer researcher at the British Columbia Cancer Research Centre in Vancouver...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature (London) Ročník 472; číslo 7343; s. 273
Hlavní autor: Ledford, Heidi
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 21.04.2011
Nature Publishing Group
Témata:
631/80/84
692/699/67/322
Animals
Biomedical research
Cancer
Cancer metastasis
Cancer therapies
Cell differentiation
Cell Movement
Cells, Cultured
Development and progression
Epithelial-Mesenchymal Transition
Health aspects
Humanities and Social Sciences
Humans
Medical research
Mice
Models, Biological
multidisciplinary
Neoplasm Metastasis - pathology
Neoplasms - pathology
news
Proteins
Reproducibility of Results
Science
Science (multidisciplinary)
United States
ISSN:0028-0836, 1476-4687, 1476-4687
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:OSI Pharmaceuticals, based in Melville, New York, is already pursuing EMT inhibitors as possible cancer treatments, as are several academic labs. "EMT is really becoming a popular subject," says Shoukat Dedhar, a cancer researcher at the British Columbia Cancer Research Centre in Vancouver and a self-avowed convert to the hypothesis. CONFLICTING IDEAS Champions of the EMT-metastasis hypothesis, including leading cancer biologist Robert Weinberg at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, say that this may simply be because EMT is so transient - once a metastatic cell has invaded a new tissue, its mesenchymal features melt away.
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-News-1
content type line 14
content type line 23
ISSN:0028-0836
1476-4687
1476-4687
DOI:10.1038/472273a